7000 Shoreline Court
South San Francisco
About IDEAYA Biosciences
Founded in 2015, IDEAYA Biosciences is a public, clinical-stage synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using DNA sequencing and other molecular diagnostics. Our approach integrates extensive capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the therapies we are developing. We are applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets. We believe this diversified approach will enable us to deliver the right medicine to the right patient to drive a more robust clinical response.
Stock Symbol: IDYA
130 articles with IDEAYA Biosciences
IDEAYA Biosciences, Inc. announced today the appointment of Bao Truong, as vice president, head of regulatory affairs.
IDEAYA Biosciences, has entered into an exclusive license agreement with Novartis to develop and commercialize Novartis' LXS196, a Phase 1 protein kinase C (PKC) inhibitor for the treatment of cancers with GNAQ and GNA11 mutations.
China’s Hillhouse Capital Group, an equity investment firm, has a new fund, Hillhouse Fund IV, with $10.6 billion ready to invest.
Yujiro S. Hata, chief executive officer of IDEAYA, will present at the Jefferies Global Healthcare Conference in New York City at 2:30 p.m. EDT on Thursday, June 7.
IDEAYA Biosciences Appoints Paul Stone, J.D., as Senior Vice President and General Counsel, Head of Operations and Mark Lackner, Ph.D. as Vice President, Head of Biomarkers and Synthetic Lethal Biology
IDEAYA Biosciences, Inc. announced the appointment of Paul Stone, J.D., as senior vice president and general counsel, head of operations, and of Mark Lackner, Ph.D. as vice president and head of biomarkers and synthetic lethal biology.
3/15/2018IDEAYA Biosciences has raised $94 million in Series B funding to drive multiple clinical studies in 2019.
Proceeds to advance multiple synthetic lethality and immuno-oncology therapies into the clinic
IDEAYA Biosciences and Cancer Research UK Announce Partnership Agreement to Develop Small Molecule Inhibitors of PARG
Data related to PARG program to be presented at American Association of Cancer Research (AACR) Annual Meeting
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.